Enveric Biosciences, Inc. · NASDAQ:ENVB
Enveric Biosciences — Investor Presentation (August 2025)
14 slides from Enveric Biosciences's investor presentation, Aug 29, 2025
Slide 1: Q3 2025 Corporate Presentation: Driving Innovation in Mental Health Therapeutics
eNVer|eG BIlosCGcien CES NEXT GENERATION MENTAL HEALTH™ Q3 2025 | CORPORATE PRESENTATION Driving Innovation in Mental Health Therapeutics Enveric.com
Slide 2: Disclaimer
Disclaimer
Slide 3: Significant Global Health Issues: Depression, Anxiety & PTSD
Significant Global Health Issues: Depression, Anxiety & PTSD WIDESPREAD LOW EFFICACY Recent Discovery: Mental health disorders are associated with impaired neural connections in key regions of the brain, which may be treatable with neuroplasticity PA vasdaq:enve
Slide 4: Big Pharma Validation of Neuroplastogen Hypothesis
Big Pharma Validation of Neuroplastogen Hypothesis 5-HT2A Receptor Agonists Induce Neuroplasticity Recent deals demonstrate Big Pharma’s appetite for 5-HT2A candidates & fi $1.9B option to license GILGAMESH | QOOvVie $1.2B acquisition of Bretisilocin Mindset @ $60M+ acquisition Sara Otsuka
Slide 5: Psychedelic Neuroplastogen Drawbacks
Psychedelic Neuroplastogen Drawbacks: Current psychedelic neuroplastogens in clinical trials cause hallucinations in the patient * Requires 8-hour clinic visits with two providers plus counseling = Often tied to mandatory psychotherapy * Costly and resource-heavy * Hallucinations deter patients and
Slide 6: Commercially Proven 5-HT1B/1D Receptor Target
Commercially Proven 5-HTIB/ID Receptor Target 5-HTIB/ID: Proven safe and effective for migraine in millions of patients by Triptan class of drugs * Simatriptan © (Imitrex) ¢ Rizatriptan o (Maxalt) Market penetration: + Zolmitriptan >100M patients treated worldwide © (Zomig) 5-HT2A and 5-HTIB Dual Re
Slide 7: EB-003 Lead Neuroplastogen
a nasdaq:ENVB EB-003 Lead Neuroplastogen: First-in-Class: Dual 5-HT2A partial agonist & 5-HTIB Agonist Non-Hallucinogenic, Orally Available 5-HT2A, * partial agonism reported to stimulate neuroplasticity in prefrontal cortex (PFC) * responsible for higher-level cognition, decision-making and social
Slide 8: EB-003: A New Treatment Standard
EB-003: A New Treatment Standard Approved Psychedelic Targeted Benefi lepressants Neuroplastogens For EB-003 Immediate efficacy Vv v Low side effects v Treatment in-clinic not required v v Large patient population Vv v Induces neuroplasticity in brain v Vv “To be proven in human clinical trials: PE
Slide 9: EB-003: Development Underway
EB-003: Development Underway Key Characteristics © Differentiated mechanism: Dual engagement of 5-HT2A and 5-HTIB receptors o Large addressable market: Multiple high-burden psychiatric conditions with limited effective treatments Compelling preclinical profile: Fast-acting, durable, and non-hallucin
Slide 10: Market Potential: Redefining the Treatment Landscape for Mental Health Disorders
Pe nasdag:ENVB Market Potential: Redefining the Treatment Landscape for Mental Health Disorders Current Approved Antidepressant Market: Global market driven by the rising prevalence of Depression 6 of patients experience inadequate relief Side Effects & Delayed Onset SSRIS/SNRIs take 4-6 weeks to wo
Slide 11: Product Pipeline
Product Pipeline Available for Partnering Stage Partner / Licensee Partner Milestone Payments EB-003 & EVM30I Series Neuroplastogens Preclinical EVM401 Series Neuroplastogens Discovery Out-Licensed Licensee EB-002 & EVM201 Series Psilocin Prodrugs Preclinical MycoMedica Life Sciences $62 Million Top
Slide 12: Management
Management Management Team Joseph Tucker, Ph.D. Chief Executive Officer Kevin Coveney, CPA Jillian Hagel, Ph.D. PA vasdaq:enve Board of Directors Michael D. Webb Board Chair George Kegler Director, Chair of the Audit Committee Frank Pasqualone Director, Chair of the Compensation and Nominating Commi
Slide 13: Potential First-in-Class Entrant to Large Mental Health Market
Potential First-in-Class Entrant to Large Mental Health Market EB-003: First in Class Drug Candidate Anticipate filing IND in Ql of 2026 and Phase | start in Q2 2026 New Drug Class Market Opportunity $30B+ market and expected to grow © Existing treatments only reach half the patients, carry signific
Slide 14: Next Generation Mental Health
wD | C Next Generation x Mental Health™ Enveric.com
Enveric Biosciences — Investor Presentation (August 2025) on 6ix